MA33097B1 - Anticorps contre la protéine tweak humaine et leurs utilisations - Google Patents

Anticorps contre la protéine tweak humaine et leurs utilisations

Info

Publication number
MA33097B1
MA33097B1 MA34141A MA34141A MA33097B1 MA 33097 B1 MA33097 B1 MA 33097B1 MA 34141 A MA34141 A MA 34141A MA 34141 A MA34141 A MA 34141A MA 33097 B1 MA33097 B1 MA 33097B1
Authority
MA
Morocco
Prior art keywords
antibodies against
against human
human tweak
tweak protein
protein
Prior art date
Application number
MA34141A
Other languages
Arabic (ar)
English (en)
Inventor
Monika Baehner
Hendrik Knoetgen
Jens Niewoehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33097B1 publication Critical patent/MA33097B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
MA34141A 2009-04-02 2010-03-30 Anticorps contre la protéine tweak humaine et leurs utilisations MA33097B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09004905 2009-04-02
PCT/EP2010/002009 WO2010115555A2 (fr) 2009-04-02 2010-03-30 Anticorps contre la protéine tweak humaine et leur utilisation

Publications (1)

Publication Number Publication Date
MA33097B1 true MA33097B1 (fr) 2012-03-01

Family

ID=40673340

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34141A MA33097B1 (fr) 2009-04-02 2010-03-30 Anticorps contre la protéine tweak humaine et leurs utilisations

Country Status (23)

Country Link
US (3) US8093006B2 (fr)
EP (2) EP2597104A1 (fr)
JP (1) JP5596777B2 (fr)
KR (1) KR101344611B1 (fr)
CN (1) CN102369219A (fr)
AR (1) AR076020A1 (fr)
AU (1) AU2010233997A1 (fr)
BR (1) BRPI1014867A2 (fr)
CA (1) CA2756245A1 (fr)
CL (1) CL2011002452A1 (fr)
CO (1) CO6362025A2 (fr)
CR (1) CR20110462A (fr)
EC (1) ECSP11011362A (fr)
IL (1) IL214355A0 (fr)
MA (1) MA33097B1 (fr)
MX (1) MX2011010117A (fr)
NZ (1) NZ594347A (fr)
PE (1) PE20120577A1 (fr)
RU (1) RU2011143903A (fr)
SG (2) SG10201404107SA (fr)
TW (1) TWI423815B (fr)
UA (1) UA105520C2 (fr)
WO (1) WO2010115555A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9526846B2 (en) 2009-08-19 2016-12-27 Safety Syringes, Inc. Patient-contact activated needle stick safety device
US9068004B2 (en) 2010-02-04 2015-06-30 University Of Louisville Research Foundation, Inc. TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration
AU2011311673B2 (en) 2010-10-05 2015-09-17 F. Hoffmann-La Roche Ag Antibodies against human TWEAK and uses thereof
CA2827759C (fr) * 2011-03-10 2018-10-16 Omeros Corporation Generation d'anticorps monoclonaux anti-fn14 par developpement accelere d'anticorps ex-vivo
SG11201406238UA (en) 2012-04-05 2014-10-30 Hoffmann La Roche Bispecific antibodies against human tweak and human il17 and uses thereof
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN103399151A (zh) * 2013-06-24 2013-11-20 上海交通大学医学院附属瑞金医院 Cxcl8细胞因子检测试剂在制备甲状腺乳头状癌的诊断试剂中的应用
US20210388096A1 (en) * 2018-10-31 2021-12-16 Astellas Pharma Inc. ANTI-HUMAN Fn14 ANTIBODY

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
DK0956351T3 (da) 1996-08-07 2006-02-20 Biogen Idec Inc Tumornekrosefaktorbeslægtet ligand
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
EP0977887A2 (fr) 1997-02-12 2000-02-09 Abbott Laboratories Element de la famille tnf utilise pour le traitement et le diagnostic d'une maladie
EP1724282B1 (fr) 1997-05-21 2013-05-15 Merck Patent GmbH Procédé de production de protéines non-immunogènes
JP2001522584A (ja) 1997-10-10 2001-11-20 ジェネンテク・インコーポレイテッド Ａｐｏ−３リガンドポリペプチド
KR20010102978A (ko) 1999-01-15 2001-11-17 아스트루 마이클 제이 면역 질환 치료를 위한 트위크 길항약 및 트위크 수용체길항약 및 이들의 용도
JP2003521836A (ja) 1999-03-04 2003-07-15 ビジョン−サイエンシズ・インコーポレイテッド 個別に制御可能な電子シャッター回路を備えた画像センサユニットセル
GB9922069D0 (en) 1999-09-17 1999-11-17 Technolog Ltd Water distribution pressure control method and apparatus
AU1226301A (en) 1999-10-22 2001-05-08 University Of Pittsburgh Stem cell engraftment-enhancing cellular proteins and their uses
AU8028400A (en) 1999-10-22 2001-05-08 Scimed Life Systems, Inc. Guided injection device
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
AU5951901A (en) 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
SI1997512T1 (sl) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
EP1811838A4 (fr) 2004-11-08 2009-07-22 Univ Maryland Tweak comme cible therapeutique permettant de traiter les maladies du systeme nerveux central associees a un oedeme cerebral et a une mort cellulaire
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
US20090068102A1 (en) 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
AU2006220825A1 (en) 2005-03-07 2006-09-14 Genentech, Inc. Methods and compositions for modulating TWEAK and FN14 activity
WO2006122187A2 (fr) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Traitement et evaluation des troubles inflammatoires
CN102441163A (zh) 2005-05-27 2012-05-09 比奥根艾迪克Ma公司 结合tweak的抗体
WO2006130429A2 (fr) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Traitement du cancer
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
MX2011010117A (es) 2011-10-14
KR101344611B1 (ko) 2013-12-30
CA2756245A1 (fr) 2010-10-14
AR076020A1 (es) 2011-05-11
WO2010115555A3 (fr) 2011-01-06
US20100255008A1 (en) 2010-10-07
CL2011002452A1 (es) 2012-03-23
RU2011143903A (ru) 2013-05-10
CN102369219A (zh) 2012-03-07
EP2414398A2 (fr) 2012-02-08
AU2010233997A1 (en) 2011-08-18
CO6362025A2 (es) 2012-01-20
US8093006B2 (en) 2012-01-10
US8852887B2 (en) 2014-10-07
JP5596777B2 (ja) 2014-09-24
JP2012521771A (ja) 2012-09-20
KR20110122868A (ko) 2011-11-11
SG175005A1 (en) 2011-11-28
TWI423815B (zh) 2014-01-21
WO2010115555A2 (fr) 2010-10-14
CR20110462A (es) 2011-09-21
US20120207750A1 (en) 2012-08-16
SG10201404107SA (en) 2014-10-30
PE20120577A1 (es) 2012-05-23
ECSP11011362A (es) 2011-10-31
BRPI1014867A2 (pt) 2016-04-12
NZ594347A (en) 2012-09-28
US20120083015A1 (en) 2012-04-05
EP2597104A1 (fr) 2013-05-29
US8883976B2 (en) 2014-11-11
IL214355A0 (en) 2011-09-27
TW201039847A (en) 2010-11-16
UA105520C2 (uk) 2014-05-26

Similar Documents

Publication Publication Date Title
MA33097B1 (fr) Anticorps contre la protéine tweak humaine et leurs utilisations
FR24C1008I1 (fr) Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire
FR17C1059I2 (fr) Composes de pyrrolopyrimidine et leurs utilisations
FR17C1022I2 (fr) Anticorps humains à grande affinité contre pcsk9
DK2437762T3 (da) Kunstige tårer og terapeutiske anvendelser
IT1392520B1 (it) Struttura di calzatura impermeabile e traspirante
BRPI0909367A2 (pt) calçado e método de fabricação do mesmo
DK2567240T4 (da) Lipidomiske biomarkører til aterosklerose og kardiovaskulær sygdom
BRPI0922486A2 (pt) microcápsulas e suas respectivas utilizações
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
DK2528625T3 (da) Pyrrolobenzodiazepiner og konjugater deraf
DK3067064T3 (da) Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
BRPI1014864A2 (pt) "implante de processos espinhosos e métodos associados"
DK2240203T3 (da) Alfa5-beta1-antistoffer og deres anvendelser
BRPI0907890A2 (pt) Implantes lacrimais e métodos relacionados
DK2129396T3 (da) Antistoffer mod ErbB3 og anvendelser deraf
DK3417701T3 (da) Genmodificerede mus og indpodning
DK3572091T3 (da) Modificerede relaxinpolypeptider og anvendelser deraf
BRPI0907109A2 (pt) lenço dental e método
DK2352509T3 (da) Hla-g-proteiner og farmaceutiske anvendelser deraf
HK1186195A1 (zh) 抗人 的抗體及其用途
BRPI1009446A2 (pt) Composições compreendendo monatina e cálcio
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
DK2274619T3 (da) Slimhindereceptor og anvendelser deraf
DK2252688T3 (da) Syntetiske phosphodiester-oligonukleotider og terapeutiske anvendelser deraf